斗地主虎牙|四人斗地主赌博

TenNor Receives QIDP Designation for TNP-2092

時間:2019年02月27日    來源:admin

February 27, 2019/Suzhou/ -- TenNor Therapeutics Limited, a clinical-stage company focused on developing differentiated infectious disease products, announced that it has received US Food and Drug Administration (FDA) Qualified Infectious Disease Product (QIDP) designation for TNP-2092 powder for injection (TNP-2092 IV), for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Catheter Related Blood Stream Infections (CRBSI) and Prosthetic Joint Infections (PJI). Benefits available under QIDP designation include priority review, fast track and 5-year extension of market exclusivity.

TNP-2092 IV is one of the leading products in TenNor’s new drug development portfolio. It is currently in Phase II clinical trials in the US. TNP-2092 is a highly differentiated product, not only active against pathogens that are resistant to available antibiotics (such as MRSA), but also active against bacteria living in biofilms. TNP-2092 IV has the potential to be used for the treatment of medical device associated bacterial biofilm infections, a major unmet medical need in infectious disease area currently requiring surgical intervention.  

斗地主虎牙 pk10计划软件免 北京十一选五 工商管理硕士哪个学校好 广东十一选五开奖直 在哪里能下载友友麻将 qq二人麻将下载 模拟炒股 天津11选5 新疆11选5走势图 球探比分 上证指数历史走势图 河北11选5开奖 湖南麻将图片 北京麻将能胡十三幺吗 广东快乐十分 山西十一选五任五遗